

## **HALF-YEAR REPORT**

Period from Januari – June 2022

Peptonic Medical AB (publ) org nr 556776-3064

([www.spotlightstockmarket.com](http://www.spotlightstockmarket.com), ticker: PMED)

### **GROUP**

#### **2022 SECOND QUARTER (Apr-Jun)**

- Net sales of products KSEK 12 354 (7 356)
- Gross profit KSEK 6 269 (4 863), Gross margin 51% (66%)
- Operating loss KSEK -8 146 (-12 271)
- Loss per share SEK -0.04 (-0.06)

#### **2022 FIRST HALF YEAR (Jan-Jun)**

- Net sales of products KSEK 21 262 (18 747)
- Gross profit KSEK 11 865 (11 439), Gross margin 56% (61%)
- Operating loss KSEK -19 021 (-18 851)
- Loss per share SEK -0.08 (-0.10)

---

### **IMPORTANT EVENTS DURING THE PERIOD**

- April 25th 2022, the Company announced that the Group is launching in the Pleasure segment through Lunette®.
- April 27th 2022, the Company announced today that its wholly owned brand Lunette® has been appointed official Menstrual Cup Partner to the United Nations (UN).
- May 27 th, 2022 the Company announced that VagiVital® VS is now commercially available in Sweden.

## From the CEO

### **Improved sales and improved results.**

It is satisfying that we in this quarter are improving both sales and earnings significantly. The improvements regard in comparison to the previous quarter and the corresponding period last year.

The sales development is explained by the positive development of sales of vaginal self-tests to international license partners in the US and the EU. We have also continued positive development of our own brand VagiVital in the home market Sweden. During the quarter, the new VagiVital VS, self-test to identify vaginal infections, was launched in Sweden.

Change in gross margin 51% (66%) in comparison with the corresponding quarter of the previous year is explained by an increasing share of sales to international partners with higher volume but lower margin. With the acquisition of CommonSense Israel, partner contracts with set prices were inherited. Prices are under renegotiation and will increase over time. In combination with increased efficiency in production, this will have a positive effect on the gross margin.

### **Well positioned to meet current social trends**

Looking forward, we see continued positive development. The company's new strategy and core business with clinically proven intimate self-care based on the diagnose/treat/prevent principle meets a strong social trend, which is reflected in growing sales and a strong order backlog. We continue with great focus on our work to create a unique and market-leading portfolio at the same time we build sales and improve results. According to the previous communicated information in the quarter one report, additional external capital will be needed.

August 18th, 2022

Erik Sundquist, VD

## COMPANY BRIEF

Peptonic Medical AB (publ) is an innovative biomedical company that conducts research on and development of drugs and medical devices in the field of women's health. Our vision is to offer safe and effective treatments for women-specific diseases and medical conditions. Peptonic Medical launched VagiVital® in July 2018. This is a hormone-free product for the treatment of vaginal atrophy and vaginal dryness. See [www.vagivital.com](http://www.vagivital.com)

Since August 2020, Lune Group Oy Ltd. is a wholly owned subsidiary of the Peptonic Medical. Lune Group Oy Ltd. is a company founded by Heli Kurjanen in 2005. The company's business concept is to lead a menstrual revolution in a positive spirit. By focusing on sustainable development, environmental issues and the promotion of sexual health, the company has developed to take the lead for the menopausal companies. Lunette® menstrual cups are an alternative to disposable menstrual protection and last for several years. The company has resellers in 50 countries and sells Lunette products to over 100 countries via its web shop. Lune Group has in the USA the subsidiary Lune North America Inc. Lunette® menstrual cups are designed, manufactured, and packaged in Finland. For more information about Lunette®, visit [www.lunette.com](http://www.lunette.com).

The company was founded in 2009 and the share has been traded since 2014 on Spotlight ([www.spotlightstockmarket.com](http://www.spotlightstockmarket.com)), short code: PMED in Stockholm.

## FINANCIAL INFORMATION

### Group

**Revenue** - Sales of goods during the second quarter amounted to SEK 12 354 (7 356) thousand. Other operating income for the quarter was SEK 329 (14) thousand. During the first half of the year, sales of goods amounted to SEK 21 262 (18 747) thousand. Other operating income for the half year was SEK 850 (4) thousand.

**Costs** - Costs for the second quarter amounted to SEK -20 829 (-19 641) thousand. Costs of goods for the second quarter amounted to SEK -6 085 (-2 493) thousand. Costs of goods for the first half year amounted to SEK -9397 (-7 308) thousand.

**Profit** - The company's profit after net financial items for the second quarter amounted to SEK -9 043 (-12 280) thousand. For the first half year the corresponding amount is SEK -20 301 (-18 918) thousand.

**Financial position and liquidity** - Cash and bank amounted to SEK 9 836 (21 140) thousand as of June 30th, 2022.

**Shareholders 'equity** - The group's shareholders' equity as of June 30, 2022, amounted to SEK 62,416 (106,526) thousand, which gives an equity / assets ratio of 67 (89) percent.

**Liabilities** - The group's liabilities, as of June 30, 2022, amounted to SEK 30,471 (13,087) thousand.

**Organization** - During the period, the average number of employees was 31 (18). At the end of the period, the number of employees was 31 (16).

**Share** - The total number of shares as of June 30, 2022 was 242,743,544 (191,639,642).

**INCOME STATEMENT**

**Peptonic Group**

KSEK	Note	3 mon apr-jun 2022	3 mon apr-jun 2021	6 mon jan-jun 2022	6 mon jan-jun 2021	12 mon jan-dec 2021
<b>Operating income</b>						
Sales of products		12 354	7 356	21 262	18 747	31 643
Other operating income		329	14	850	4	622
<b>Total operating income</b>		<b>12 683</b>	<b>7 370</b>	<b>22 111</b>	<b>18 751</b>	<b>32 265</b>
<b>Operating expenses</b>						
Cost of goods		-6 085	-2 493	-9 397	-7 308	-12 573
Other external expenses	1	-8 715	-11 874	-19 245	-20 906	-45 690
Personnel costs		-5 653	-2 989	-11 256	-6 202	-19 430
Depreciation		-879	-877	-1 737	-1 754	-27 055
Other operating costs		502	-1 408	502	-1 432	-1 234
<b>Total operating expenses</b>		<b>-20 829</b>	<b>-19 641</b>	<b>-41 132</b>	<b>-37 602</b>	<b>-105 983</b>
<b>Operating loss</b>		<b>-8 146</b>	<b>-12 271</b>	<b>-19 021</b>	<b>-18 851</b>	<b>-73 718</b>
Net financial income/expense		-897	-9	-1 280	-67	30
<b>Loss before taxes</b>		<b>-9 043</b>	<b>-12 280</b>	<b>-20 301</b>	<b>-18 918</b>	<b>-73 688</b>
Taxes		0	-14	0	-14	0
<b>Net loss for the period</b>		<b>-9 043</b>	<b>-12 294</b>	<b>-20 301</b>	<b>-18 932</b>	<b>-73 688</b>

**BALANCE SHEET**

**Peptonic Group**

KSEK	Note	30-jun 2022	30-jun 2021	31-dec 2021
<b>Assets</b>				
<b>Non-Current assets</b>				
Intangible assets	2	50 879	76 125	52 210
Goodwill/badwill	2	0	0	
Tangible assets	3	4 142	1 300	4 204
Financial assets		0	0	0
<b>Total non-current assets</b>		<b>55 021</b>	<b>77 425</b>	<b>56 413</b>
<b>Current assets</b>				
Stock		15 325	6 422	10 323
On going fund raising		0	0	0
Other receivbles		11 582	13 821	5 166
Tax receivable		0	-2	524
Prepaid expenses and accrued income		1 123	807	920
Liquid assets		9 836	21 140	10 153
<b>Total current assets</b>		<b>37 866</b>	<b>42 188</b>	<b>27 086</b>
<b>Total assets</b>		<b>92 887</b>	<b>119 613</b>	<b>83 500</b>
<b>Equity and liabilities</b>				
<b>Equity</b>				
<b>Ristricted equity</b>				
Share capital		24 274	19 164	19 164
Ongoing right issues		0	0	0
Reserves		11 186	10 068	9 617
Other contributed capital		270 942	249 592	247 337
Profit or loss brought forward incl year result		-243 987	-172 298	-224 101
<b>Total equity</b>	3	<b>62 416</b>	<b>106 526</b>	<b>52 017</b>
<b>Current liabilities</b>				
Liabilities interest bearing		7 471	8 387	6 219
Trade payables		16 022	-94	15 347
Other payables		1 365	928	2 885
Prepaid income and accrued expenses		5 615	3 866	7 032
<b>Total current liabilities</b>		<b>30 471</b>	<b>13 087</b>	<b>31 483</b>
<b>Total equity and liabilities</b>	4	<b>92 887</b>	<b>119 613</b>	<b>83 500</b>

**STATEMENT OF CASH FLOW**  
**Peptonic Group**

KSEK	Note	<b>6 mon jan-jun 2022</b>	<b>6 mon jan-jun 2021</b>	<b>12 mon jan-dec 2021</b>
<b>CASH FLOW FROM OPERATIONS BEFORE CHANGES IN WORKING CAPITAL</b>				
Operating profit/loss		-20 301	-18 918	-73 688
Non-cash flow items		1 737	1 754	26 840
Paid tax		0	-14	0
<b>NET CASH FLOW FROM OPERATING ACTIVITIES BEFORE CHANGES IN WORKING CAPITAL</b>		<b>-18 564</b>	<b>-17 178</b>	<b>-46 848</b>
Increase (-) decrease (+) inventory		-5 002	-289	-4 190
Increase (-) decrease (+) receivables		-6 095	-4 684	3 333
Increase (-) decrease (+) liabilities		-1 686	-3 531	7365
<b>NET CASH FLOW FROM OPERATING ACTIVITIES</b>		<b>-31 347</b>	<b>-25 681</b>	<b>-40 340</b>
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>				
Investment in immaterial assets, net		-211	-176	-1 256
Investment in material asset, incl subsidiaries		0	185	-3 024
Investment in financial assets, net		0	0	0
Divestment / reduction of financial assets		282	-	0
<b>NET CASH FLOW FROM INVESTING ACTIVITIES</b>		<b>71</b>	<b>9</b>	<b>-4 280</b>
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>				
Rights issue		33 729	7 500	7 500
Issue expenses		-3 445	0	-15
Bridgeloan		675	0	7 500
<b>NET CASH FLOW FROM FINANCING ACTIVITIES</b>		<b>30 959</b>	<b>7 500</b>	<b>14 985</b>
<b>TOTAL CASH FLOW FOR THE YEAR</b>		<b>-317</b>	<b>-18 172</b>	<b>-29 159</b>
Cash and cash equivalents at beginning of period		10 153	39 312	39 312
<b>CASH AND CASH EQUIVALENTS AT END OF THE YEAR</b>		<b>9 836</b>	<b>21 140</b>	<b>10 153</b>

## NOTE

### Accounting principles

This interim report has been prepared in accordance with the Annual Accounts Act (Chapter 9. Interim Report) and the Swedish Accounting Standards Board's general advice, BFNAR 2012:1 Annual Report and consolidated (K3-rules).

### Note 1 – Related-party transactions

#### Group/Peptonic Medical AB

During the period until 24<sup>th</sup> of May 2022, companies represented by members of the Board of Directors were contracted as consultants. Total compensation for consultancy services amounted to SEK 408 (855) thousand and is related to business development services. All transactions between related parties are based on market conditions. No other key executives or their immediate family members have been directly or indirectly involved in any business transaction with the Company that is or was unusual in its character or terms and conditions and took place during the period.

KSEK	<b>2022</b> Jan-Jun	2021 Jan-Jun
Consulting fees Board of Directors	408	855
<b>Total</b>	<b>408</b>	<b>855</b>

### Note 2 – Intangible assets (KSEK)

Patent and development costs are capitalized and depreciated in 20 years from the first revenue that the group receives. The depreciations started in year 2019. Capitalized patent and development costs are estimated to result in future revenues for the Group. From 2019 they are depreciated at 5% per annum. Which corresponds to the estimated life of the commercial rights. The group's goodwill is fully written down in 2021. In 2021, costs for the acquisition and integration have also burdened the group's results.



**Note 2**

**Peptonic Group**

	<b>30-jun 2022</b>	<b>30-jun 2021</b>	<b>31-dec 2021</b>	<b>31-dec 2020</b>
<b>Capitalized development costs</b>				
Accumulated acquisition value				
Opening balance	52 900	51 996	51 996	49 457
Sold out and Other disposals	0	-9	0	0
Capitalizations during the period	0	118	904	2539
	<b>52 900</b>	<b>52 105</b>	<b>52 900</b>	<b>51 996</b>
Accumulated depreciation value	-7 980	-5 171	-5 171	-2473
Deprecation of the year	-1 388	-689	-2 809	-2 698
	<b>-9 368</b>	<b>-5 860</b>	<b>-7 980</b>	<b>-5 171</b>
<b>Net booked amount at end of period</b>	<b>43 533</b>	<b>46 245</b>	<b>44 921</b>	<b>46 825</b>
<b>Patents och licenses</b>				
Accumulated acquisition value				
Opening balance	8 438	8 086	8 086	7 803
Sold out and Other disposals	0	0	0	0
Capitalizations during the period	211	0	352	283
	<b>8 649</b>	<b>8 086</b>	<b>8 438</b>	<b>8 086</b>
Depreciation				
Accumulated depreciation value	-1148	-841	-841	-535
Deprecation of the year	-154	-153	-307	-306
	<b>-1302</b>	<b>-994</b>	<b>-1148</b>	<b>-841</b>
<b>Net booked amount at end of period</b>	<b>7 347</b>	<b>7 092</b>	<b>7 290</b>	<b>7 245</b>
<b>Group goodwill</b>				
Accumulated acquisition values				
At the beginning of the period	23 495	23 495	23 495	0
Activations for the period	0	0	0	23 495
	<b>23 495</b>	<b>23 495</b>	<b>23 495</b>	<b>23 495</b>
Depreciation at the beginning of the period	-23 495	0	0	0
This year's depreciations	0	0	-23 495	0
Outgoing depreciation	-23 495	0	-23 495	0
<b>Net booked amount at end of period</b>	<b>0</b>	<b>23 495</b>	<b>0</b>	<b>23 495</b>
<b>Total intangible assets</b>	<b>50 879</b>	<b>76 832</b>	<b>52 210</b>	<b>77 565</b>

### Note 3 - Tangible fixed assets

#### Group

The Group has activated tools to produce products.

### Note 4 – Equity and liabilities

#### Group

There is SEK 16 022 thousand of interest-bearing debt in the Group.

#### KEY FIGURES

##### Peptonic Group

	<b>6 mon jan-jun 2022</b>	<b>6 mon jan-jun 2021</b>	<b>12 mon jan-dec 2021</b>	<b>12 mon jan-dec 2020</b>
Sales goods, KSEK	21 262	18 747	31 643	21 283
Gross profit sales goods, KSEK	11 865	11 439	19 070	13 089
Gross margin, %	56%	61%	60%	61%
Operating profit, KSEK	-19 021	-37 602	-73 718	-31 053
Return on equity,%	-142	-22	-87	-31
Equity ratio,%	67	89	62	88
Earnings per share, SEK	-0.08	-0.10	-0.38	-0.19
Liquidity per share, SEK	0.04	0.11	0.05	0.24
Equity per share, SEK	0.26	0.56	0.27	0.72
Share price per closing, SEK	0.49	1.30	0.63	1.73
Share price/Equity per share, SEK	1.91	2.09	2.30	2.39
Equity per share, SEK	<b>242 743 544</b>	<b>191 639 642</b>	<b>191 639 642</b>	<b>162 911 613</b>

## FINANSIELL INFORMATION

### Parent company Peptonic Medical AB

**Revenue** - Sales of goods during the second quarter amounted to SEK 4 634 (766) thousand. Other operating income for the quarter was SEK 0 (3) thousand. During the first half of the year, sales of goods amounted to SEK 6 903 (2 888) thousand. Other operating income for the half year was SEK 0 (16) thousand.

**Costs** - Costs for the second quarter amounted to SEK -7 391 (-10 399) thousand. Costs of goods for the second quarter amounted to SEK -2 487 (-192) thousand. Costs for the first half year amounted to SEK -14 530 (-15 286) thousand. Costs of goods for the first half year amounted to SEK -3 307 (-1 399) thousand.

**Profit** - The company's profit after net financial items for the second quarter amounted to SEK -3 615 (-9 630) thousand. For the first half year the corresponding amount is SEK -14 530 (-15 286) thousand.

**Financial position and liquidity** - Cash and bank amounted to SEK 5 562 (19 430) thousand as of June 30th, 2022.

**Shareholders' equity** - The group's shareholders' equity as of June 30, 2022, amounted to SEK 117,696 (115,779) thousand, which gives an equity / assets ratio of 84 (96) percent. During the quarter, the company received a net of SEK 30,3 million in newly issued capital.

**Liabilities** - The group's liabilities, as of June 30, 2022, amounted to SEK 22,412 (5,358) thousand. Of which is approx. KSEK 16 000 thousand interest-bearing liabilities.

**Organization** - During the period, the average number of employees was 3 (3). At the end of the period, the number of employees was 3 (3).

**Share** - The total number of shares as of June 30, 2022, was 242,743,544 (191,639,642).

**INCOME STATEMENT**  
**Peptonic Medical AB**

KSEK	Note	3 mon apr-jun 2022	3 mon apr-jun 2021	6 mon jan-jun 2022	6 mon jan-jun 2021	12 mon jan-dec 2021
<b>Operating income</b>						
Sales of products		2 642	766	4 292	2 888	6 551
Intercompany sales		1 992	0	2 611	0	881
Other operating income		0	3	0	16	130
<b>Total operating income</b>		<b>4 634</b>	<b>769</b>	<b>6 903</b>	<b>2 904</b>	<b>7 562</b>
<b>Operating expenses</b>						
Cost of goods		-2 487	-192	-3 307	-1 399	-3 151
Other external expenses	1	-2 773	-7 040	-6 760	-9 381	-23 903
Personnel costs		-1 330	-1 064	-2 967	-3 018	-11 569
Depreciation		-700	-695	-1 395	-1 390	-2 782
Other operating costs		-101	-1 408	-101	-98	-1 076
<b>Total operating expenses</b>		<b>-7 391</b>	<b>-10 399</b>	<b>-14 530</b>	<b>-15 286</b>	<b>-42 481</b>
<b>Operating loss</b>		<b>-2 757</b>	<b>-9 630</b>	<b>-7 627</b>	<b>-12 382</b>	<b>-34 919</b>
Net financial income/expense		-858	0	-1 251	0	-10
<b>Loss before taxes</b>		<b>-3 615</b>	<b>-9 630</b>	<b>-8 878</b>	<b>-12 382</b>	<b>-34 928</b>
Taxes		0	0	0	0	0
<b>Net loss for the period</b>		<b>-3 615</b>	<b>-9 630</b>	<b>-8 878</b>	<b>-12 382</b>	<b>-34 928</b>

**BALANCE SHEET**

**Peptonic Medical AB**

KSEK	Note	30-jun 2022	30-jun 2021	31-dec 2021
<b>Assets</b>				
<b>Non-Current assets</b>				
Intangible assets	2	50 317	51 748	51 496
Tangible assets		41	0	46
Financial assets	3	53 450	42 752	53 450
<b>Total non-current assets</b>		<b>103 809</b>	<b>94 500</b>	<b>104 993</b>
<b>Current assets</b>				
Stock		2 845	1 847	2 060
On going fund raising		0	0	0
Other receivbles		2 653	5 217	838
Group company receivables		24 897	0	8 199
Tax receivable		0	-2	0
Prepaid expenses and accrued income		341	145	496
Liquid assets		5 562	19 430	2 849
<b>Total current assets</b>		<b>36 299</b>	<b>26 637</b>	<b>14 441</b>
<b>Total assets</b>		<b>140 108</b>	<b>121 137</b>	<b>119 434</b>
<b>Equity and liabilities</b>				
<b>Equity</b>				
<b>Ristricted equity</b>				
Share capital		24 274	19 164	19 164
Ongoing right issues		0	0	0
Development Cost Fund		11 186	10 068	9 617
<b>Non- restrictes equity</b>				
Share premiun reserv non-restricted		272 044	249 572	248 439
Profit or loss brought forward		-180 930	-121 291	-146 002
Net loss for the period		-8 878	-41 734	-34 928
<b>Total equity</b>	3	<b>117 696</b>	<b>115 779</b>	<b>96 290</b>
<b>Current liabilities</b>				
Liabilities interest bearing		1 995	2 024	1 801
Trade payables		15 994	0	15 000
Other payables		1 066	873	652
Group company debts		0	0	0
Prepaid income and accrued expenses		3 356	2 461	5 691
<b>Total current liabilities</b>		<b>22 412</b>	<b>5 358</b>	<b>23 144</b>
<b>Total equity and liabilities</b>	4	<b>140 108</b>	<b>121 137</b>	<b>119 434</b>

## Note 1 – Related-party transactions

### Parentcompany Peptonic Medical AB

During the period until 24<sup>th</sup> of May 2022, companies represented by members of the Board of Directors were contracted as consultants. Total compensation for consultancy services amounted to SEK 408 (855) thousand and is related to business development services. All transactions between related parties are based on market conditions. No other key executives or their immediate family members have been directly or indirectly involved in any business transaction with the Company that is or was unusual in its character or terms and conditions and took place during the period.

KSEK	<b>2022</b>	<b>2021</b>
	<b>Jan-Jun</b>	<b>Jan-Jun</b>
Consulting fees Board of Directors	408	855
<b>Total</b>	<b>408</b>	<b>855</b>

## Note 2 – Intangible assets (KSEK)

Patent and development costs are capitalized and depreciated in 20 years from the first revenue that the group receives. The depreciations started in year 2019. Capitalized patent and development costs are estimated to result in future revenues for the Group. From 2019 they are depreciated at 5% per annum. Which corresponds to the estimated life of the commercial rights.

**Note 2**

<b>Peptonic Medical AB</b>	<b>30-jun</b>	<b>30-jun</b>	<b>31-dec</b>
<b>Capitalized development costs</b>	<b>2022</b>	<b>2021</b>	<b>2021</b>
Accumulated acquisition value			
Opening balance	51 625	50 721	50 721
Sold out and Other disposals	0	0	0
Capitalizations during the period	0	118	904
	<b>51 625</b>	<b>50 839</b>	<b>51 625</b>
Accumulated depreciation value	-7 419	-4 946	-4 946
Deprecation of the year	-1 236	-1 236	-2 473
	<b>-8 655</b>	<b>-6 182</b>	<b>-7 419</b>
<b>Net booked amount at end of period</b>	<b>42 970</b>	<b>44 657</b>	<b>44 206</b>
<b>Patents och licenses</b>			
Accumulated acquisition value			
Opening balance	8 438	8 086	8 086
Sold out and Other disposals	0	0	0
Capitalizations during the period	211	0	352
	<b>8 649</b>	<b>8 086</b>	<b>8 438</b>
Depreciation			
Accumulated depreciation value	-1148	-841	-841
Deprecation of the year	-154	-153,498	-307
	<b>-1302</b>	<b>-994,498</b>	<b>-1148</b>
<b>Net booked amount at end of period</b>	<b>7 347</b>	<b>7 092</b>	<b>7 290</b>
<b>Total intangible assets</b>	<b>50 317</b>	<b>51 748</b>	<b>51 496</b>

**Note 3 - Financial fixed assets**

**Parentcompany**

As of June 30, 2021, a total of SEK 53,450 thousand has been capitalized for the acquisition of subsidiaries.

**Note 4 – Equity and liabilities**

**Parentcompany**

There is SEK 15 994 thousand of interest-bearing debt in the company.

**This interim report has not been reviewed by the Company's auditors.**

The Board of Directors and the CEO certifies that the interim report gives a fair overview of the business, position and profit or loss of the Company.

### **FINANCIAL CALENDER**

Quarterly report, 3	2022-11-10
Year-end report, 2022	2023-02-24

**Stockholm den 18 August 2022**

Jan Bardell, Chairmen of the Board

Susanne Axelsson, Board member

Lena Munkhammar, Board member

Anders Norling, Board member

Erik Sundquist, CEO

### **For more information please contact:**

Erik Sundquist, CEO PEPTONIC medical AB. Phone: +46 722 499 043

*Note: This document has been prepared in both Swedish and English. The Swedish version shall govern in case of differences between the two documents. The document contains certain statements about the Company's operating environment and future performance. These statements should only be regarded as reflective of prevailing interpretations. No guarantees can be made that these statements are free from errors.*